The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer

European Journal of Surgical Oncology

Volumn 31, Issue 4, 2005, Pages 325-330

  Poston, Graeme J ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG INDICATION; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; LIVER CANCER; LIVER DISEASE; LIVER METASTASIS; LIVER RESECTION; META ANALYSIS; NATIONAL HEALTH SERVICE; OUTCOMES RESEARCH; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; SYSTEMATIC REVIEW; UNITED KINGDOM;

EID: 17144367674     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.01.008     Document Type: Note

References (32)

1. J.S.J. Ferguson M. Summerhayes S. Masters S. Schey I.E. Smith New treatments for advanced cancer: An approach to prioritization Br J Cancer 83 2000 1268-1273
2. W. Scheitheuer H. Rosen G.V. Kornek et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer BMJ 306 1993 752-755
3. T. Andre C. Louvet E. Raymond et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen Ann Oncol 9 1998 1251-1253
4. T. Andre M.A. Bensmaine C. Louvet et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen J Clin Oncol 17 1999 3560-3568
5. A. de Gramont A. Figer M. Seymour et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938-2947
6. J.Y. Douillard D. Cunningham A.D. Roth et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial Lancet 355 2000 1041-1047
7. H. Bismuth R. Adam F. Levi et al. Resection of non-resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy Ann Surg 224 1996 509-522
8. S. Giacchetti M. Itzhaki G. Gruia et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery Ann Oncol 10 1999 663-669
9. R. Adam E. Avisar A. Ariche et al. Five year survival following hepatic resection after neoadjuvant therapy for non-resectable colorectal (liver) metastases Ann Surg Oncol 8 2001 347-353
10. L. Walsh G.J. Poston The potential to increase curative liver resection rates in metastatic colorectal cancer Eur J Surg Oncol 28 2002 812-814
11. A. Grothey B. Deschler H. Kroening et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) vs weekly high-dose 24 h 5-FU infusion/FA+oxaliplatin (OXA)(FUFOX) an advanced colorectal cancer (ACRC) Proc Am Soc Clin Oncol 21 2002 [abstract no. 512]
12. M.L. Rothenberg A.M. Oza R.H. Bigelow et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial J Clin Oncol 21 2003 2059-2069
13. M.L. Rothenberg A.M. Oza B. Burger et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin Proc Am Soc Clin Oncol 22 2003 252 [abstract 1011]
14. P. Comella B. Massidda G. Filipelli et al. Biweekly oxaliplatin (OXA) or irinotecan (IRI) with high dose folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC). Southern Italy Cooperative Oncology Group (SICOG 0103) randomised study Proc Am Soc Clin Oncol 22 2003 280 [abstract 1123]
15. H. Kalofonos G. Aravantinos P. Kosmidis et al. Randomised phase II study of CPT-11 plus leucovorin (LV) and 5-fluorouracil (5FU) versus oxaliplatin (OXA) plus LV and 5FU) as first line treatment in advanced colorectal cancer (CRC) Proc Am Soc Clin Oncol 22 2003 268 [abstract 1074]
16. S.R. Alberts J.H. Donohue M.R. Mahoney et al. Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liver: A North Central Cancer Treatment Group (NCCTG) phase II study Proc Am Soc Clin Oncol 22 2003 263 [abstract 1053]
17. Y. Kenemitsu T. Kato T. Hirai K. Yasui Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer Br J Surg 91 2004 112-120
18. H. Vogelsang S. Haas C. Hierholzer et al. Factors influencing survival after resection of pulmonary metastases from colorectal cancer Br J Surg 91 2004 1066-1071
19. A. Grothey D. Sargent R.M. Goldberg H.J. Schmoll Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 2004 1209-1214
20. R.M. Goldberg D.J. Sargent R.F. Morton et al. A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23-30
21. R.M. Goldberg D.J. Sargent R.F. Morton et al. N9741: FOLFOX (oxaliplatin (oxal)/5-fluorouracil (5-FU)/leucovorin or reduced dose R-IFL (CPT-11+5FU/LV) in advanced colorectal cancer (CRC): Final efficacy data from an intergroup study Proc Am Soc Clin Oncol 23 2004 275 [abstract 3621]
22. J. Souglakos N. Ziras A. Polyzos et al. Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicente randomized phase III trial Proc Am Soc Clin Oncol 23 2004 253 [abstract 3530]
23. G. Lopez-Vivanco A. Munoz J.M. Mane et al. Combination of oxaliplatin and capecitabine (CAPOX) in first and second-line treatment for metastatic colorectal carcinoma (MCRC) Proc Am Soc Clin Oncol 23 2004 295 [abstract 3701]
24. Y. Miyata K. Shirao A. Ohtsu et al. Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU)/l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC): A phase I/II study Proc Am Soc Clin Oncol 23 2004 296 [abstract 3705]
25. A. Tsvaraidis A. Athanasiadis N. Pissanidis et al. Weekly oxaliplatin (OXA), 5-fluorouracil (FU) and leucovorin (LV) as first line treatment for advanced colorectal cancer (CRC) Proc Am Soc Clin Oncol 23 2004 297 [abstract 3712]
26. Y.Z. Patt J. Liebmann D. Diamandidis et al. Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial Proc Am Soc Clin Oncol 23 2004 271
27. A. De Gramont A. Cervantes T. Andre et al. OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer Proc Am Soc Clin Oncol 23 2004 251 [abstract 3525]
28. S. Giacchetti G. Bjarnason C. Garufi et al. First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL4-10) versus 2-day FOLFOX2. A multicentre randomized phase III trial of the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer (EORTC 05963) Proc Am Soc Clin Oncol 23 2004 252 [abstract 3526]
29. A. Munoz V. Alonso P. Escudero et al. Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC) Proc Am Soc Clin Oncol 23 2004 273 [abstract 3610]
30. C. Tournigand T. Andre E. Achille et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomised GERCOR study J Clin Oncol 22 2004 229-237
31. G. Pascal B. Nordlinger J.-Y. Douillard et al. Resection after chemotherapy (CT) with irinotecan (CPT) for initially unresectable liver metastases (LM) from colorectal cancer Proc Am Soc Clin Oncol 23 2004 293 [abstract 3692]
32. F. Quenet B. Nordlinger M. Rivoire et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (folfirinox): A prospective phase II trial Proc Am Soc Clin Oncol 23 2004 273 [abstract 3613]